Importance of accurate EPCAM deletion characterization to prevent misdiagnosis of Lynch syndrome

Horton C, MS¹; Mar-Heyming R, PhD¹; Hernandez F, PhD¹; Marsh APL, PhD¹; Harrison S, PhD¹; Grzybowski J, MS¹, Richardson ME, PhD¹, Kostecki D, MS¹, Lau C, PhD¹; Chao E, MD, PhD^{1,2}; Hampel H, MS³

1) Ambry Genetics 2) University of California, Irvine, School of Medicine 3) City of Hope

<u>chorton@ambrygen.com</u>




BACKGROUND

Prior to the introduction of NGS, *EPCAM* deletion screening was typically performed by one MLPA kit throughout the country. The only MLPA kit available does not have probe coverage 5' of exon 3, making it difficult to determine if a deletion spans the entire gene. Phenotypes of individuals with isolated whole *EPCAM* deletions are not well described and may have different clinical implications than individuals with partial deletions.

METHODS

All cases with a gross deletion including *EPCAM* identified at a single laboratory from 2011-2021 were evaluated to determine how many had a known or possible full *EPCAM* deletion detected via MLPA or microarray. Amsterdam criteria II (AC) and revised Bethesda criteria (BC) were assessed in families with full and partial deletions.

FIGURE 2. Cohort Selection








FIGURE 3. Sample MLPA Result



meet criteria or Bethesda meet criteria n=67 n=1 n=9

FIGURE 4. Isolated *EPCAM* Deletion Size



Unknown Deletion Size

Known Full Deletion

Known Partial Deletion

21% of individuals with isolated EPCAM deletions may have a full deletion.

Re-evaluation in individuals not meeting criteria should be considered.

TAKE HOME POINTS

- 1. Isolated whole-gene EPCAM deletions do not appear to cause Lynch syndrome.
- 2. Some patients with EPCAM-associated Lynch syndrome may be misdiagnosed and eligible for re-evaluation.